1. Home
  2. AXTI vs MGNX Comparison

AXTI vs MGNX Comparison

Compare AXTI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXTI
  • MGNX
  • Stock Information
  • Founded
  • AXTI 1986
  • MGNX 2000
  • Country
  • AXTI United States
  • MGNX United States
  • Employees
  • AXTI N/A
  • MGNX N/A
  • Industry
  • AXTI Semiconductors
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AXTI Technology
  • MGNX Health Care
  • Exchange
  • AXTI Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • AXTI 94.4M
  • MGNX 99.7M
  • IPO Year
  • AXTI 1998
  • MGNX 2013
  • Fundamental
  • Price
  • AXTI $5.31
  • MGNX $1.72
  • Analyst Decision
  • AXTI Strong Buy
  • MGNX Hold
  • Analyst Count
  • AXTI 4
  • MGNX 6
  • Target Price
  • AXTI $4.60
  • MGNX $3.20
  • AVG Volume (30 Days)
  • AXTI 1.9M
  • MGNX 630.9K
  • Earning Date
  • AXTI 10-30-2025
  • MGNX 11-04-2025
  • Dividend Yield
  • AXTI N/A
  • MGNX N/A
  • EPS Growth
  • AXTI N/A
  • MGNX N/A
  • EPS
  • AXTI N/A
  • MGNX N/A
  • Revenue
  • AXTI $86,080,000.00
  • MGNX $165,495,000.00
  • Revenue This Year
  • AXTI N/A
  • MGNX N/A
  • Revenue Next Year
  • AXTI $29.24
  • MGNX N/A
  • P/E Ratio
  • AXTI N/A
  • MGNX N/A
  • Revenue Growth
  • AXTI N/A
  • MGNX 303.47
  • 52 Week Low
  • AXTI $1.13
  • MGNX $0.99
  • 52 Week High
  • AXTI $5.67
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • AXTI 69.71
  • MGNX 50.98
  • Support Level
  • AXTI $4.37
  • MGNX $1.66
  • Resistance Level
  • AXTI $5.48
  • MGNX $1.83
  • Average True Range (ATR)
  • AXTI 0.48
  • MGNX 0.12
  • MACD
  • AXTI 0.03
  • MGNX 0.00
  • Stochastic Oscillator
  • AXTI 80.83
  • MGNX 53.70

About AXTI AXT Inc

AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: